

HR 6501

Prescription Drug and Medical Device Price Review Board Act of 2016

Congress: 114 (2015–2017, Ended)

Chamber: House

Policy Area: Health

Introduced: Dec 8, 2016

Current Status: Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.

Latest Action: Referred to the Subcommittee on Courts, Intellectual Property, and the Internet. (Dec 22, 2016)

Official Text: <https://www.congress.gov/bill/114th-congress/house-bill/6501>

Sponsor

Name: Rep. DeLauro, Rosa L. [D-CT-3]

Party: Democratic • **State:** CT • **Chamber:** House

Cosponsors (8 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Doggett, Lloyd [D-TX-35]	D · TX		Dec 8, 2016
Rep. Honda, Michael M. [D-CA-17]	D · CA		Dec 8, 2016
Rep. Kaptur, Marcy [D-OH-9]	D · OH		Dec 8, 2016
Rep. McDermott, Jim [D-WA-7]	D · WA		Dec 8, 2016
Rep. Moore, Gwen [D-WI-4]	D · WI		Dec 8, 2016
Rep. Schakowsky, Janice D. [D-IL-9]	D · IL		Dec 8, 2016
Rep. Welch, Peter [D-VT-At Large]	D · VT		Dec 8, 2016
Rep. Cummings, Elijah E. [D-MD-7]	D · MD		Dec 23, 2016

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Dec 8, 2016
Judiciary Committee	House	Referred to	Dec 22, 2016
Ways and Means Committee	House	Referred To	Dec 8, 2016

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Prescription Drug and Medical Device Price Review Board Act of 2016

This bill establishes the Prescription Drug and Medical Device Price Review Board within the Food and Drug Administration. Each manufacturer of a prescription drug or medical device that is sold in the United States must submit to the board:

- each type of prescription drug and medical device that it sells in the United States, or in a country that is a member of the Organization for Economic Co-operation and Development;
- the price charged by the manufacturer for the drug or device; and
- the costs of the manufacturer to produce them.

The board must establish a formula for determining whether the average manufacturer price of a prescription drug or medical device over an annual quarter is an excessive price. Manufacturers may not charge excessive prices. Individuals may petition the board to determine whether the price for a prescription drug or medical device is excessive.

The board may subject violators to reduced patent terms, civil penalties, and increased Medicaid rebates. The bill amends the Internal Revenue Code to impose a tax on the sale of prescription drugs or medical devices that have excessive prices.

The board must allow individuals to import from approved countries prescription drugs and devices that are comparable to prescription drugs and devices with excessive prices.

Actions Timeline

- **Dec 22, 2016:** Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.
- **Dec 8, 2016:** Introduced in House
- **Dec 8, 2016:** Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.